Sponsor

Immunogen Inc.

United States 830 Winter Street, 02451-1477, United States

About the sponsor

Research activity is centered on platinum-resistant advanced high-grade epithelial ovarian cancer, with additional interest in primary peritoneal cancer and fallopian tube cancer.

Advanced epithelial ovarian cancer
Primary peritoneal cancer
Fallopian tube cancer

The clinical focus is on malignancies that remain difficult to treat after standard platinum-based therapy.

About Specializations

Immunogen Inc. runs clinical trials in conditions such as Peritoneal sarcoma, Fallopian tube cancer, Ovarian epithelial cancer, among others.

All trials

Ongoing trials

Clinical trials registered by this sponsor – none is enrolling right now.

Quick filters

1 clinical trial

Peritoneal sarcoma+2

Not recruiting

Registered drugNo placebo

Study of Mirvetuximab Soravtansine compared to standard chemotherapy in women with platinum-resistant advanced ovarian cancer with high folate receptor expression

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Paclitaxel
Sponsor:Immunogen Inc.

Contact Research Centre

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Join now →